Ann Hanham

Board Member @SCYNEXIS, Inc.

Carmel Highlands, CA, US
EMAILS
a••••••@htgmolecular.com
MOBILE NUMBERS
+16•••••••44

Signup · Get unlimited contacts

WORK HISTORY

Jan 2006 — Present

Board Member @SCYNEXIS, Inc.

View department →

Jersey City, NJ, US

SCYNEXIS (NASDAQ: SCYX).SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. SCYNEXIS scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. The company is developing their lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. Additional information:

EDUCATION

N/A

The University of British Columbia

PhD

SKILLS

Private EquityStrategyDue DiligenceExecutive ManagementRegulatory AffairsCommercializationStart-UpsStrategic AlliancesInvestor RelationsOncologyFinancial ModelingLifesciencesVenture CapitalPortfolio ManagementBusiness DevelopmentPharmaceutical IndustryLife SciencesDrug DevelopmentHardware DiagnosticsBusiness PlanningMergers & AcquisitionsLicensingMolecular BiologyCorporate DevelopmentProgram ManagementEntrepreneurshipInvestmentsValuationR&DClinical ResearchInvestment BankingManagementTechnology TransferProduct DevelopmentMedicineBiotechnologyStrategic PlanningEquitiesHealthcareClinical Development

ABOUT ANN HANHAM

Specialties: Board member (public and private), life sciences investing.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.